Advertisement

Topics

WuXi AppTec Completes First Phase of $125 Million Biologics Manufacturing Facility

03:49 EDT 23 Sep 2016 | ChinaBio Today

WuXi Biologics, a division of WuXi AppTec, a China CRO/CMO, has completed construction of the first phase of a commercial-scale cGMP biologics perfusion manufacturing facility in Wuxi city, China. The entire project, announced in 2015, is expected to cost $150 million. The first phase includes two 1000L disposable bioreactors for perfusion processes. WuXi says the plant is the largest perfusion biologics manufacturing facility currently operating in Asia that uses disposable bioreactors. More details....

Share this with colleagues:  

Original Article: WuXi AppTec Completes First Phase of $125 Million Biologics Manufacturing Facility

NEXT ARTICLE

More From BioPortfolio on "WuXi AppTec Completes First Phase of $125 Million Biologics Manufacturing Facility"

Quick Search
Advertisement
 

Relevant Topics

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...